Find out if you qualify
Breast cancer is diagnosed in more than 1.3 million women worldwide each year and is the leading cause of cancer-related death in women. It is estimated that at least 5 percent of breast cancer cases result from inherited mutations or alterations in BRCA1 and BRCA2 genes. Women with these mutations have a lifetime risk of developing breast cancer of 40-85 percent. Males with BRCA2 mutations also carry an increased risk of breast cancer. The Brocade 3 study is a research study for men and women with HER-2 negative metastatic or locally advanced BRCA-associated breast cancer.
This research study is currently seeking female and male volunteers, ages 18 and older, who have been diagnosed with HER-2 negative metastatic or locally advanced BRCA-associated breast cancer. The purpose of this research study is to evaluate the safety and effectiveness of an investigational drug, veliparib (or placebo), in combination with two chemotherapeutic drugs that are commonly used for the treatment of breast cancer.
Compensation for travel may be provided. More information on this study can be found by visiting www.Brocade3Study.com to see if you may qualify.